Learn About New Treatments for Osteoporosis

OSUWexnerbloglogo2014 Learn About New Treatments for Osteoporosis. On this CME webcast, we’re going to bring you up to date on the latest recommendations for the management of osteoporosis and on the latest developments in pharmacologic treatment. Joining our moderator in the studio is endocrinologist and Associate Professor of Internal Medicine, Dr. Steven Ing. And endocrinologist and also Associate Professor of Internal Medicine, Dr. Laura Ryan.

View a video introduction of this webcast

What you’ll learn in this webcast

As a result of this educational activity, webcast participants will be able to: DISCUSS 2017 ACP guidelines on osteoporosis; DISCUSS studies subsequent to guidelines; UNDERSTAND the latest data on therapy for postmenopausal osteoporosis using evidence based clinical studies; and IMPROVE comfort in deciding on initial therapy to choose for patients at high risk for fracture, then monitoring that choice over time.

You’ll also learn about the following:

  • New developments in osteoporosis treatment
  • Choosing a bisphosphonate
  • Calcium & vitamin D

You can find this and many other MedNet21 programs on the OSU – CCME website.

Call our MedNet21 Program Manager at 614.293.3473 for more details about subscribing to MedNet21 as a hospital or as an individual. You can also e-mail him at derrick.freeman@osumc.edu.

Managing Complications of Chemotherapy Discussed on CME Webcast

OSUWexnerbloglogo2014 Managing Complications of Chemotherapy Discussed on CME Webcast. On this CME webcast, to update us is medical oncologist and Associate Professor of Internal Medicine from the Ohio State University and the James Cancer Hospital, Dr. Erin Bertino. And also from the James Cancer Hospital, Assistant Professor of Internal Medicine, Dr. Edmund Folefac.

View a video introduction of this webcast

What you’ll learn in this webcast

As a result of this educational activity, webcast participants will be able to: RECOGNIZE the differences in toxicity for three categories of oncology therapy: cytotoxic chemotherapy, targeted therapy, and immunotherapy; and UNDERSTAND basic management of the most common toxicities of chemotherapy, targeted therapy, and immunotherapy.

You’ll also learn about the following:

  • Evolution of targeted therapies and immunotherapy
  • What to expect with cancer treatment

You can find this and many other MedNet21 programs on the OSU – CCME website.

Call our MedNet21 Program Manager at 614.293.3473 for more details about subscribing to MedNet21 as a hospital or as an individual. You can also e-mail him at derrick.freeman@osumc.edu.

CME Webcast Teaches on Preventive Cardiology

OSUWexnerbloglogo2014 CME Webcast Teaches on Preventive Cardiology. The best way to improve outcomes in cardiovascular disease is to not get it in the first place and today on MedNet21, we are going to show you what you can do to prevent heart disease in your patients. Let me welcome today’s guests. Dr. Wesley Milks is a cardiologist and Assistant Professor of Internal Medicine and Kelly Bartsch is a pharmacist specializing in lipid management.

View a video introduction of this webcast

What you’ll learn in this webcast

As a result of this educational activity, webcast participants will be able to: REVIEW
the mechanisms of action of the major medication classes utilized in the 2018 multi-society cholesterol guidelines; and UNDERSTAND the influence of the new cardiovascular outcomes trials for ezetimibe and the PCSK9 inhibitors on the new cholesterol guidelines; DEMONSTRATE understanding of key atherosclerotic risk and risk-enhancing factors as well as of recent pivotal lipid lowering treatment guidelines; and SELECT the appropriate target of lipid lowering therapy (e.g. LDL-C or non-HDL-C) with respect to the patient’s comorbid metabolic conditions.

You’ll also learn about the following:

  • Cholesterol level goals
  • Indications for medical treatment of lipids
  • Follow-up of patients started on cholesterol lowering drugs
  • Monitoring of cholesterol lowering drugs
  • CRP and other inflammatory markers

You can find this and many other MedNet21 programs on the OSU – CCME website.

Call our MedNet21 Program Manager at 614.293.3473 for more details about subscribing to MedNet21 as a hospital or as an individual. You can also e-mail him at derrick.freeman@osumc.edu.

Learn the Latest on Hepatocellular Carcinoma Viewing CME Webcast

OSUWexnerbloglogo2014 Learn the Latest on Hepatocellular Carcinoma Viewing CME Webcast. Here in the United States, the incidence of hepatocellular carcinoma is rising. The way that we approach cancer of the liver has changed over the past 20 years and today on MedNet, we are going to bring you up to date on the epidemiology, screening, diagnosis, and treatment of hepatocellular carcinoma. Joining us today is hepatologist and Assistant Professor of Internal Medicine, Dr. Lanla F. Conteh.

View a video introduction of this webcast

What you’ll learn in this webcast

As a result of this educational activity, webcast participants will be able to: UNDERSTAND the epidemiology of hepatocellular carcinoma in the United States; and RECOGNIZE which patients should be screened for hepatocellular carcinoma.

You’ll also learn about the following:

  • The rising incidence of hepatocellular carcinoma
  • New directions in treatment of hepatocellular carcinoma
  • Imaging test of choice in suspected hepatocellular carcinoma
  • How to biopsy suspected hepatocellular carcinoma
  • Viral hepatitis risk factors for hepatocellular carcinoma
  • Fibrolamellar hepatocellular carcinoma

You can find this and many other MedNet21 programs on the OSU – CCME website.

Call our MedNet21 Program Manager at 614.293.3473 for more details about subscribing to MedNet21 as a hospital or as an individual. You can also e-mail him at derrick.freeman@osumc.edu.

Learn About New Therapies for Type 2 Diabetes

OSUWexnerbloglogo2014 Learn About New Therapies for Type 2 Diabetes. 25 years ago, the management of type II diabetes was easy. You started a patient on a sulfonylurea and then if their glucose level didn’t improve, you added in NPH insulin. But things have changed. And today, we have better and safer medications to treat diabetes. Which is a good thing because the prevalence of diabetes over the past 25 years has grown enormously and we really needed new treatments to fight against this public health threat. But with new treatments can come confusion about which to use in different clinical situations. Joining our moderator on this CME webcast, to update us on the management of type 2 diabetes is endocrinologist and Assistant Professor of Internal Medicine from the Ohio State University, Dr. Joshua Joseph.

View a video introduction of this webcast

What you’ll learn in this webcast

As a result of this educational activity, webcast participants will be able to: DESCRIBE the role of new medical therapies in hypoglycemia; and DESCRIBE the role of new medical therapies in cardiovascular disease.

You’ll also learn about the following:

  • New directions in the treatment of type 2 diabetes
  • Hemoglobin A1C targets
  • Treatment of type 2 diabetes when medication cost is a consideration
  • New glucose monitoring technologies

You can find this and many other MedNet21 programs on the OSU – CCME website.

Call our MedNet21 Program Manager at 614.293.3473 for more details about subscribing to MedNet21 as a hospital or as an individual. You can also e-mail him at derrick.freeman@osumc.edu.